495 related articles for article (PubMed ID: 8531999)
21. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
Bourhis J; De Vathaire F; Wilson GD; Hartmann O; Terrier-Lacombe MJ; Boccon-Gibod L; McNally NJ; Lemerle J; Riou G; Bénard J
Cancer Res; 1991 Jan; 51(1):33-6. PubMed ID: 1988094
[TBL] [Abstract][Full Text] [Related]
22. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
[TBL] [Abstract][Full Text] [Related]
23. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
Gehring M; Berthold F; Edler L; Schwab M; Amler LC
Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
[TBL] [Abstract][Full Text] [Related]
24. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
Ohtsu K; Hiyama E; Ichikawa T; Matsuura Y; Yokoyama T
Clin Cancer Res; 1997 Jul; 3(7):1221-8. PubMed ID: 9815803
[TBL] [Abstract][Full Text] [Related]
25. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
26. [Sensibility and specificity of N-myc oncogene with respect to other prognostic factors in 15 neuroblastomas].
Queizán A; García-Miguel P; Belló MJ; Castresana JC; Rey JA; Pestaña A
Cir Pediatr; 1995 Jul; 8(3):96-8. PubMed ID: 8527322
[TBL] [Abstract][Full Text] [Related]
27. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
28. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
Mora J; Cheung NK; Chen L; Qin J; Gerald W
Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
[TBL] [Abstract][Full Text] [Related]
29. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
30. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
[TBL] [Abstract][Full Text] [Related]
31. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
32. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification.
Caron H; van Sluis P; van Hoeve M; de Kraker J; Bras J; Slater R; Mannens M; Voûte PA; Westerveld A; Versteeg R
Nat Genet; 1993 Jun; 4(2):187-90. PubMed ID: 8102298
[TBL] [Abstract][Full Text] [Related]
33. Comparative genomic hybridization (CGH) analysis of neuroblastomas--an important methodological approach in paediatric tumour pathology.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Boecker W; Lampert F; Stoerkel S
J Pathol; 1997 Apr; 181(4):394-400. PubMed ID: 9196436
[TBL] [Abstract][Full Text] [Related]
34. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma.
Caron H
Med Pediatr Oncol; 1995 Apr; 24(4):215-21. PubMed ID: 7700165
[TBL] [Abstract][Full Text] [Related]
35. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
[TBL] [Abstract][Full Text] [Related]
36. Allelic loss of chromosome 18q and prognosis in colorectal cancer.
Jen J; Kim H; Piantadosi S; Liu ZF; Levitt RC; Sistonen P; Kinzler KW; Vogelstein B; Hamilton SR
N Engl J Med; 1994 Jul; 331(4):213-21. PubMed ID: 8015568
[TBL] [Abstract][Full Text] [Related]
37. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
38. Overall genomic pattern is a predictor of outcome in neuroblastoma.
Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
[TBL] [Abstract][Full Text] [Related]
39. Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients.
Brack T; Scholz RB; Milde-Langosch K; Heinsohn S; Löning T; Kabisch H
Cancer Detect Prev; 1992; 16(3):185-92. PubMed ID: 1458508
[TBL] [Abstract][Full Text] [Related]
40. Chromosome 1p allelic loss in neuroblastoma: prognosis, genomic imprinting and 1;17 translocations.
Caron H; van Sluis P; van Roy N; Beks L; Maes P; Pereira do Tanque R; Slater R; de Kraker J; Speleman F; Voûte PA
Prog Clin Biol Res; 1994; 385():35-42. PubMed ID: 7972230
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
